SLC2A6

Summary

SLC2A6 (solute carrier family 2 member 6, HGNC:11011) is a protein-coding gene on chromosome 9q34.2, encoding Solute carrier family 2, facilitated glucose transporter member 6 (Q9UGQ3). Probable sugar transporter that acts as a regulator of glycolysis in macrophages.

Hexose transport into mammalian cells is catalyzed by a family of membrane proteins, including SLC2A6, that contain 12 transmembrane domains and a number of critical conserved residues.

Source: NCBI Gene 11182 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cardiomyopathy (Limited, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 95 total
• MANE Select transcript: NM_017585

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11011
Approved symbol	SLC2A6
Name	solute carrier family 2 member 6
Location	9q34.2
Locus type	gene with protein product
Status	Approved
Aliases	GLUT9, GLUT6, HSA011372
Ensembl gene	ENSG00000160326
Ensembl biotype	protein_coding
OMIM	606813
Entrez	11182

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 18 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000371897, ENST00000371899, ENST00000414172, ENST00000432868, ENST00000485978, ENST00000888406, ENST00000888407, ENST00000888408, ENST00000917277, ENST00000917278, ENST00000917279, ENST00000917280, ENST00000917281, ENST00000917282, ENST00000949324, ENST00000949325, ENST00000949326, ENST00000949327, ENST00000949328

RefSeq mRNA: 2 — MANE Select: NM_017585 NM_001145099, NM_017585

CCDS: CCDS48052, CCDS6975

Canonical transcript exons

ENST00000371899 — 10 exons

Exon	Start	End
ENSE00001051504	133473980	133474088
ENSE00001269134	133473415	133473600
ENSE00001693142	133478254	133478416
ENSE00001902440	133478968	133479099
ENSE00003460377	133473105	133473250
ENSE00003485250	133477035	133477241
ENSE00003486246	133476237	133476336
ENSE00003603040	133475400	133475611
ENSE00003662123	133474961	133475113
ENSE00003847282	133471094	133472176

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 93.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.2218 / max 411.6961, expressed in 1686 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103012	15.3749	1571
103013	5.2273	1538
103010	0.3942	171
103011	0.2254	113

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	93.39	gold quality
monocyte	CL:0000576	92.35	gold quality
leukocyte	CL:0000738	91.97	gold quality
prefrontal cortex	UBERON:0000451	86.88	gold quality
frontal cortex	UBERON:0001870	86.39	gold quality
right frontal lobe	UBERON:0002810	86.01	gold quality
primary visual cortex	UBERON:0002436	85.52	gold quality
Brodmann (1909) area 9	UBERON:0013540	85.38	gold quality
blood	UBERON:0000178	85.32	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.31	gold quality
superior frontal gyrus	UBERON:0002661	84.99	gold quality
cerebral cortex	UBERON:0000956	84.78	gold quality
anterior cingulate cortex	UBERON:0009835	84.32	gold quality
hypothalamus	UBERON:0001898	83.72	gold quality
spleen	UBERON:0002106	83.71	gold quality
substantia nigra	UBERON:0002038	82.12	gold quality
Ammon’s horn	UBERON:0001954	81.12	gold quality
right hemisphere of cerebellum	UBERON:0014890	80.38	gold quality
brain	UBERON:0000955	80.34	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	80.31	gold quality
putamen	UBERON:0001874	80.20	gold quality
vermiform appendix	UBERON:0001154	79.72	gold quality
lymph node	UBERON:0000029	79.38	gold quality
temporal lobe	UBERON:0001871	79.18	gold quality
cortical plate	UBERON:0005343	79.12	gold quality
amygdala	UBERON:0001876	78.97	gold quality
apex of heart	UBERON:0002098	78.85	gold quality
cerebellum	UBERON:0002037	78.76	gold quality
cerebellar hemisphere	UBERON:0002245	78.70	gold quality
cerebellar cortex	UBERON:0002129	78.68	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	5.15
E-ANND-3	no	1.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting SLC2A6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-3191-3P	99.45	63.94	356
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-6882-3P	98.23	67.01	1119
HSA-MIR-1914-5P	97.83	66.21	807
HSA-MIR-3652	97.71	65.43	1890
HSA-MIR-4741	97.69	64.14	883
HSA-MIR-4675	97.69	64.82	774
HSA-MIR-4430	97.47	65.61	1813
HSA-MIR-3620-5P	97.42	63.95	792
HSA-MIR-1587	96.95	64.03	932
HSA-MIR-3139	96.68	66.77	652
HSA-MIR-642B-5P	96.37	67.26	745

Literature-anchored findings (GeneRIF, showing 3)

• The expression pattern of GLUT9 is reported in newly diagnosed esophageal adenocarcinoma by means of immunohistochemistry. (PMID:19554504)
• The NF-kappaB signalling pathway regulates GLUT6 expression in endometrial cancer. (PMID:32512041)
• SREBP2/Rab11s/GLUT1/6 network regulates proliferation and migration of glioblastoma. (PMID:36327817)

Cross-species orthologs

45 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc2a6	ENSDARG00000058731
mus_musculus	Slc2a6	ENSMUSG00000036067
rattus_norvegicus	Slc2a6	ENSRNOG00000005900
drosophila_melanogaster	Glut3	FBGN0015230
drosophila_melanogaster	sut4	FBGN0028560
drosophila_melanogaster	sut3	FBGN0028561
drosophila_melanogaster	sut2	FBGN0028562
drosophila_melanogaster	sut1	FBGN0028563
drosophila_melanogaster	CG4607	FBGN0029932
drosophila_melanogaster	CG15406	FBGN0031517
drosophila_melanogaster	CG8837	FBGN0031520
drosophila_melanogaster	CG3285	FBGN0031522
drosophila_melanogaster	CG15408	FBGN0031523
drosophila_melanogaster	CG7882	FBGN0033047
drosophila_melanogaster	Tret1-2	FBGN0033644
drosophila_melanogaster	CG8249	FBGN0034045
drosophila_melanogaster	CG6484	FBGN0034247
drosophila_melanogaster	CG14160	FBGN0036066
drosophila_melanogaster	nebu	FBGN0036316
drosophila_melanogaster	CG1208	FBGN0037386
drosophila_melanogaster	CG14606	FBGN0037485
drosophila_melanogaster	CG14605	FBGN0037486
drosophila_melanogaster	CG6901	FBGN0038414
drosophila_melanogaster	CG17929	FBGN0038415
drosophila_melanogaster	CG17930	FBGN0038416
drosophila_melanogaster	Tret1-1	FBGN0050035
drosophila_melanogaster	CG32053	FBGN0052053
drosophila_melanogaster	CG32054	FBGN0052054
drosophila_melanogaster	CG33281	FBGN0053281
drosophila_melanogaster	CG33282	FBGN0053282
drosophila_melanogaster	Srg2	FBGN0262007
drosophila_melanogaster	CG42826	FBGN0262008
caenorhabditis_elegans		WBGENE00008730
caenorhabditis_elegans		WBGENE00010684
caenorhabditis_elegans		WBGENE00010811
caenorhabditis_elegans		WBGENE00012536
caenorhabditis_elegans		WBGENE00013074
caenorhabditis_elegans		WBGENE00016431
caenorhabditis_elegans		WBGENE00017382
caenorhabditis_elegans		WBGENE00019207
caenorhabditis_elegans		WBGENE00019547
caenorhabditis_elegans		WBGENE00019548
caenorhabditis_elegans		WBGENE00019549
caenorhabditis_elegans		WBGENE00019550
caenorhabditis_elegans		WBGENE00043980

Paralogs (13): SLC2A3 (ENSG00000059804), SLC2A9 (ENSG00000109667), SLC2A1 (ENSG00000117394), SLC2A11 (ENSG00000133460), SLC2A8 (ENSG00000136856), SLC2A5 (ENSG00000142583), SLC2A12 (ENSG00000146411), SLC2A13 (ENSG00000151229), SLC2A2 (ENSG00000163581), SLC2A14 (ENSG00000173262), SLC2A4 (ENSG00000181856), SLC2A7 (ENSG00000197241), SLC2A10 (ENSG00000197496)

Protein

Protein identifiers

Solute carrier family 2, facilitated glucose transporter member 6 — Q9UGQ3 (reviewed: Q9UGQ3)

Alternative names: Glucose transporter type 6

All UniProt accessions (3): Q9UGQ3, F2Z2F6, F2Z3K7

UniProt curated annotations — full annotation on UniProt →

Function. Probable sugar transporter that acts as a regulator of glycolysis in macrophages. Does not transport glucose.

Subcellular location. Lysosome membrane.

Tissue specificity. Highly expressed in brain, spleen and peripheral blood leukocytes.

Induction. By lipopolysaccharide (LPS).

Similarity. Belongs to the major facilitator superfamily. Sugar transporter (TC 2.A.1.1) family. Glucose transporter subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UGQ3-1	1	yes
Q9UGQ3-2	2

RefSeq proteins (2): NP_001138571, NP_060055* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003663	Sugar/inositol_transpt	Family
IPR005828	MFS_sugar_transport-like	Family
IPR005829	Sugar_transporter_CS	Conserved_site
IPR020846	MFS_dom	Domain
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR050549	MFS_Trehalose_Transporter	Family

Pfam: PF00083

UniProt features (35 total): topological domain 13, transmembrane region 12, binding site 3, chain 1, region of interest 1, short sequence motif 1, modified residue 1, glycosylation site 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UGQ3-F1	81.69	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 174; 286–287; 418

Post-translational modifications (1): 23

Glycosylation sites (1): 370

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-189200	Cellular hexose transport

MSigDB gene sets: 227 (showing top): GOBP_CARBOHYDRATE_TRANSPORT, GOBP_NUCLEOSIDE_DIPHOSPHATE_METABOLIC_PROCESS, GOCC_VACUOLAR_MEMBRANE, BOYAULT_LIVER_CANCER_SUBCLASS_G2, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS, ENGELMANN_CANCER_PROGENITORS_UP, GOBP_NUCLEOSIDE_TRIPHOSPHATE_METABOLIC_PROCESS

GO Biological Process (6): regulation of glycolytic process (GO:0006110), hexose transmembrane transport (GO:0008645), fructose transmembrane transport (GO:0015755), transmembrane transport (GO:0055085), dehydroascorbic acid transport (GO:0070837), D-glucose transmembrane transport (GO:1904659)

GO Molecular Function (5): fructose transmembrane transporter activity (GO:0005353), transmembrane transporter activity (GO:0022857), dehydroascorbic acid transmembrane transporter activity (GO:0033300), D-glucose transmembrane transporter activity (GO:0055056), protein binding (GO:0005515)

GO Cellular Component (4): lysosomal membrane (GO:0005765), plasma membrane (GO:0005886), membrane (GO:0016020), lysosome (GO:0005764)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
SLC-mediated transmembrane transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hexose transmembrane transport	2
hexose transmembrane transporter activity	2
glycolytic process	1
regulation of purine nucleotide catabolic process	1
regulation of generation of precursor metabolites and energy	1
regulation of carbohydrate catabolic process	1
regulation of ATP metabolic process	1
monosaccharide transmembrane transport	1
transport	1
cellular process	1
vitamin transport	1
fructose transmembrane transport	1
transporter activity	1
transmembrane transport	1
dehydroascorbic acid transport	1
vitamin transmembrane transporter activity	1
binding	1
lysosome	1
lytic vacuole membrane	1
membrane	1
cell periphery	1
cellular anatomical structure	1
lytic vacuole	1

Protein interactions and networks

STRING

2118 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC2A6	H7C1H1	H7C1H1	742
SLC2A6	SLC50A1	Q9BRV3	453
SLC2A6	PCMTD2	Q9NV79	445
SLC2A6	SLC5A4	Q9NY91	436
SLC2A6	SLC5A1	P13866	435
SLC2A6	PRPSAP1	Q14558	433
SLC2A6	CHST10	O43529	427
SLC2A6	SLC7A6	Q92536	427
SLC2A6	PRDM13	Q9H4Q3	393
SLC2A6	RAB11FIP5	Q9BXF6	385
SLC2A6	SLC2A3	P11169	384
SLC2A6	SLC16A5	O15375	384
SLC2A6	NFKBIL1	Q9UBC1	383
SLC2A6	SLC12A9	Q9BXP2	380
SLC2A6	EARS2	Q5JPH6	377
SLC2A6	SLC2A11	Q9BYW1	377

IntAct

12 interactions, top by confidence:

A	B	Type	Score
TMEM14B	SLC2A6	psi-mi:“MI:0915”(physical association)	0.560
OPALIN	BTAF1	psi-mi:“MI:0914”(association)	0.530
SLC2A6	CHRM5	psi-mi:“MI:0915”(physical association)	0.370
NS3	C15orf61	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC2A6	SCGB2A1	psi-mi:“MI:0914”(association)	0.350
SLC10A4	ILVBL	psi-mi:“MI:0914”(association)	0.350
SLC2A6	BRIX1	psi-mi:“MI:0914”(association)	0.350
SLC30A6	PSMD14	psi-mi:“MI:0914”(association)	0.350
TMEM14B	SLC2A6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (15): SCGB1D1 (Affinity Capture-MS), LACRT (Affinity Capture-MS), SCGB2A1 (Affinity Capture-MS), SLC2A6 (Two-hybrid), SLC2A6 (Affinity Capture-MS), SLC2A6 (Proximity Label-MS), SLC2A6 (Two-hybrid), LACRT (Affinity Capture-MS), SCGB2A1 (Affinity Capture-MS), SLC2A6 (Affinity Capture-MS), SLC2A6 (Affinity Capture-MS), BCLAF1 (Affinity Capture-MS), BRIX1 (Affinity Capture-MS), TMEM106B (Affinity Capture-MS), SLC2A6 (Affinity Capture-MS)

ESM2 similar proteins: A6QLW8, A7MBE0, A9CB25, B2GV36, O02713, O08966, O15244, O15245, O35956, O57379, O70577, O70594, O75751, O76082, O77504, O88446, O88909, Q1RPP5, Q3YAW7, Q4W8A2, Q5R540, Q5R5H7, Q5RLM2, Q63089, Q66J54, Q6A4L0, Q6DFR1, Q6NUB3, Q6NYN7, Q70BM6, Q80UJ1, Q863T6, Q8BXB6, Q8HY24, Q8MJI6, Q8MK48, Q8VC69, Q91WU2, Q92959, Q961J5

Diamond homologs: A0A0H2VG78, A1Z8N1, A4ZYQ5, A5LGM7, A9ZSY2, A9ZSY3, B0WC46, B3MG58, B3NSE1, B4GAP7, B4HNS0, B4HNS1, B4J913, B4KR05, B4LPX5, B4MYA4, B4P624, B4QBN2, B4QBN3, C0SPB2, O04036, O04249, O34718, O44827, O52733, O62787, P0AE24, P0AE25, P0AEP1, P0AEP2, P0C6A1, P11166, P11167, P11169, P13355, P14142, P14246, P14672, P15686, P17809

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

95 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	4
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1629 predictions. Top by Δscore:

Variant	Effect	Δscore
9:133473977:TAC:T	donor_loss	1.0000
9:133473978:A:AC	donor_gain	1.0000
9:133473978:A:AG	donor_loss	1.0000
9:133473979:C:A	donor_loss	1.0000
9:133473979:C:CC	donor_gain	1.0000
9:133474084:GGGGG:G	acceptor_gain	1.0000
9:133474085:GGGG:G	acceptor_gain	1.0000
9:133474086:GGG:G	acceptor_gain	1.0000
9:133474087:GG:G	acceptor_gain	1.0000
9:133474088:GCT:G	acceptor_loss	1.0000
9:133474089:C:A	acceptor_loss	1.0000
9:133474089:C:CC	acceptor_gain	1.0000
9:133474093:C:CT	acceptor_gain	1.0000
9:133474094:G:T	acceptor_gain	1.0000
9:133474955:TCTCA:T	donor_loss	1.0000
9:133474956:CTCAC:C	donor_loss	1.0000
9:133474957:TCACC:T	donor_loss	1.0000
9:133474958:CACCA:C	donor_loss	1.0000
9:133474959:A:AC	donor_gain	1.0000
9:133474959:ACCA:A	donor_loss	1.0000
9:133474960:C:CC	donor_gain	1.0000
9:133474960:CCAG:C	donor_gain	1.0000
9:133475109:CTGCT:C	acceptor_gain	1.0000
9:133475112:CT:C	acceptor_gain	1.0000
9:133475114:C:CC	acceptor_gain	1.0000
9:133475319:T:TA	donor_gain	1.0000
9:133477029:CCTTA:C	donor_loss	1.0000
9:133477030:CTTA:C	donor_loss	1.0000
9:133477031:TTA:T	donor_loss	1.0000
9:133477032:TA:T	donor_loss	1.0000

AlphaMissense

3215 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:133474004:G:T	R338S	0.995
9:133473150:G:C	S441R	0.994
9:133473150:G:T	S441R	0.994
9:133473152:T:G	S441R	0.994
9:133476260:C:T	G180E	0.993
9:133477164:G:C	S111R	0.993
9:133477164:G:T	S111R	0.993
9:133477166:T:G	S111R	0.993
9:133477069:C:T	G143D	0.992
9:133476323:T:A	E159V	0.991
9:133473236:A:G	W413R	0.990
9:133473236:A:T	W413R	0.990
9:133473238:C:T	G412D	0.990
9:133473239:C:G	G412R	0.990
9:133475524:G:C	S217W	0.990
9:133476317:G:T	A161D	0.990
9:133477132:C:T	G122D	0.990
9:133473221:A:G	W418R	0.989
9:133473221:A:T	W418R	0.989
9:133473233:C:G	G414R	0.989
9:133474061:C:G	G319R	0.989
9:133474061:C:T	G319R	0.989
9:133477070:C:G	G143R	0.989
9:133478351:C:T	G53E	0.989
9:133472120:G:C	S475R	0.988
9:133472120:G:T	S475R	0.988
9:133472122:T:G	S475R	0.988
9:133473415:C:G	G408R	0.988
9:133474995:A:G	L298P	0.987
9:133475019:C:T	G290D	0.987

dbSNP variants (sampled 300 via entrez): RS1000030934 (9:133479015 G>A), RS1000617866 (9:133475943 C>T), RS1000758339 (9:133476294 G>A), RS1000926789 (9:133475920 ATTTCT>A), RS1000959424 (9:133471570 C>G), RS1000979171 (9:133471568 G>A), RS1001252540 (9:133478732 C>T), RS1001309597 (9:133475330 C>A,T), RS1001450810 (9:133480446 G>A), RS1001483152 (9:133480245 A>G), RS1001696630 (9:133473815 C>A,G,T), RS1001747463 (9:133470943 C>T), RS1003381852 (9:133476605 G>A), RS1003699795 (9:133472700 C>G,T), RS1003959799 (9:133479251 G>C,T)

Disease associations

OMIM: gene MIM:606813 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
cardiomyopathy	Limited	Autosomal dominant

Mondo (1): cardiomyopathy (MONDO:0004994)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000123_1	Urate levels	2.000000e-16
GCST000227_2	Uric acid levels	1.000000e-11
GCST003854_49	Gut microbiota (functional units)	3.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0004761	uric acid measurement
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009202	Cardiomyopathies	C14.280.238

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Class II transporters

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cisplatin	affects cotreatment, increases expression	2
Valproic Acid	decreases expression, increases expression, increases methylation	2
Cyclosporine	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
honokiol	decreases reaction, increases expression	1
propionaldehyde	increases expression	1
nuciferine	increases expression, decreases reaction	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression, increases abundance	1
butyraldehyde	increases expression	1
manganese chloride	decreases expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, affects response to substance	1
epigallocatechin gallate	increases expression	1
pentanal	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
deguelin	decreases expression	1
2-palmitoylglycerol	increases expression	1
monomethylarsonous acid	decreases expression	1
K 7174	increases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
pyrimidifen	decreases expression	1
thifluzamide	decreases expression	1
abrine	increases expression	1
pyrachlostrobin	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
picoxystrobin	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Aldehydes	increases expression	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4L8	HCT116-SLC2A6-KO-c6	Cancer cell line	Male
CVCL_D4L9	HCT116-SLC2A6-KO-c8	Cancer cell line	Male
CVCL_E0NT	Ubigene HeLa SLC2A6 KO	Cancer cell line	Female
CVCL_TM83	HAP1 SLC2A6 (-) 1	Cancer cell line	Male
CVCL_XT14	HAP1 SLC2A6 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	PHASE4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	PHASE4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	PHASE4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	PHASE4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	PHASE4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	PHASE4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	PHASE4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	PHASE4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	PHASE4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	PHASE4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05718128	PHASE4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	PHASE4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00170183	PHASE3	COMPLETED	Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
NCT00270387	PHASE3	COMPLETED	A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00321295	PHASE3	COMPLETED	Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
NCT00483197	PHASE3	UNKNOWN	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
NCT00490321	PHASE3	UNKNOWN	VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00626028	PHASE3	COMPLETED	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
NCT01013714	PHASE3	UNKNOWN	Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01217827	PHASE3	COMPLETED	Implantable Cardioverter-Defibrillator Use in the VA System
NCT01648634	PHASE3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02924285	PHASE3	COMPLETED	Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease
NCT03860935	PHASE3	COMPLETED	Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT04166331	PHASE3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05175066	PHASE3	COMPLETED	Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT06158698	PHASE3	RECRUITING	CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06563895	PHASE3	RECRUITING	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06846086	PHASE3	RECRUITING	Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
NCT07116473	PHASE3	NOT_YET_RECRUITING	To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT00185250	PHASE2	COMPLETED	Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
NCT00490347	PHASE2	COMPLETED	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
NCT00694161	PHASE2	COMPLETED	The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy